Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza virus subunit vaccine
- Development stage
- Approved
- Lead developer
- Fosun Apexvac
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The influenza virus subunit vaccine is a purified protein subunit vaccine developed by Dalian Yalifeng Biopharmaceutical (a subsidiary of Fosun Pharma) for the prevention of seasonal influenza. Unlike split-virion vaccines, which contain all components of the disrupted virus, this subunit formulation consists only of the essential surface antigens—hemagglutinin (HA) and neuraminidase (NA). These antigens are isolated and purified from inactivated influenza viruses, typically grown in embryonated chicken eggs. By removing internal viral proteins and genetic material, the subunit vaccine aims to provide a favorable safety profile with lower reactogenicity while maintaining the ability to induce protective neutralizing antibodies. The vaccine is available in trivalent and quadrivalent forms and is administered via intramuscular injection to individuals across various age groups, including children and the elderly.
- Brand names
- 孚洛克Fu Luo KeFLU-K
- Other names
- influenza subunit vaccine流感病毒亚单位疫苗
02
Targets
BCR (Immunoglobulin G B Cell Receptor)NeuraminidaseHA0 (Influenza B virus hemagglutinin)Human T-cell receptor (TCR) recognizing influenza hemagglutinin (HA)/neuraminidase (NA)-derived peptides presented on MHC class II
Beyond the preview
Go deeper on influenza virus subunit vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza virus subunit vaccine.